A study in mouse models of allogeneic stem cell transplantation with donor-derived CD19 chimeric antigen receptor (CAR) T cells for the treatment of relapsed B cell malignancies indicates that T cell exhaustion might have a role in preventing allogeneic reactivity of CD19 CAR T cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
Journal of Experimental & Clinical Cancer Research Open Access 26 August 2021
-
Engineering better chimeric antigen receptor T cells
Experimental Hematology & Oncology Open Access 02 December 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cruz, C.R.Y. et al. Blood 122, 2965–2973 (2013).
Terakura, S. et al. Blood 119, 72–82 (2012).
Kochenderfer, J.N. et al. Blood 122, 4129–4139 (2013).
Brudno, J.N. et al. J. Clin. Oncol. 34, 1112–1121 (2016).
Kebriaei, P. et al. J. Clin. Invest. 126, 3363–3376 (2016).
Ghosh, A. et al. Nat. Med. 23, 242–249 (2017).
Jacoby, E. et al. Blood 127, 1361–1370 (2016).
Frigault, M.J. et al. Cancer Immunol. Res. 3, 356–367 (2015).
Long, A.H. et al. Nat. Med. 21, 581–590 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.E.H. has received research funding from Celgene for studies of genetically modified T cells. M.M. has no conflicts to declare.
Rights and permissions
About this article
Cite this article
Mamonkin, M., Heslop, H. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med 23, 147–148 (2017). https://doi.org/10.1038/nm.4276
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4276
This article is cited by
-
CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
Journal of Experimental & Clinical Cancer Research (2021)
-
Engineering better chimeric antigen receptor T cells
Experimental Hematology & Oncology (2020)